Articles by R. Christian Moreton - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by R. Christian Moreton

Toward Expanding Understanding

A revised book on process analytical technology could be valuable to novices and experts.
Mar 2, 2011

A revised book on process analytical technology could be valuable to novices and experts.

Flexible Approaches to Accommodate Excipient Variability Using the Principles of QbD

The authors review new regulatory expectations and describe potential approaches to accommodate excipient variability. This article is part of PharmTech's supplement "Solid Dosage and Excipients 2010."
May 1, 2010

The authors review new regulatory expectations and describe potential approaches to accommodate excipient variability. This article is part of PharmTech's supplement "Solid Dosage and Excipients 2010."

The Continuing Story of Nanoparticles

A book illustrates the potential for nanoparticulate drug delivery, and how much about them remains to be understood.
Nov 2, 2007

A book illustrates the potential for nanoparticulate drug delivery, and how much about them remains to be understood.

Manufacturing One Trend at a Time

Change is inevitable, as is contract manufacturing. But which companies will survive the drifts?
Oct 2, 2007

Change is inevitable, as is contract manufacturing. But which companies will survive the drifts?

Functionality and Performance of Excipients

Oct 1, 2006

This article provides an overview of functionality, functionality-related characteristics, and excipients performance.

Excipient Functionality

May 2, 2004

The author suggests that an excipient's functionality can only be determined in the context of a specific formulation and manufacturing process.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FindPharma Custom Search
Click here